Clinical Report: Exploring Off-Label Use of Sotatercept in Children with PAH
Background
Pulmonary arterial hypertension (PAH) in children is a severe condition with poor outcomes compared to adults. Sotatercept, a novel agent targeting pulmonary vascular remodeling, has shown promise in adult trials but lacks pediatric data.
Data Highlights
Parameter
Baseline
24 Weeks
PVRI (WU·m²)
Data not specified
Data not specified
mPAP (mmHg)
Data not specified
Data not specified
PCWP (mmHg)
Data not specified
Data not specified
Key Findings
Seven pediatric patients were included in the analysis.
All patients had severe PAH and were on maximal triple therapy prior to sotatercept initiation.
Right heart catheterization was performed before and after 24 weeks of treatment.
Initial dosing of sotatercept was 0.3 mg/kg, with uptitration to 0.7 mg/kg as tolerated.
Monitoring for adverse effects included complete blood counts and clinical assessments for symptoms like epistaxis.
Clinical Implications
Clinicians should consider the potential benefits and risks when evaluating treatment options for this challenging population.
Conclusion
This retrospective analysis highlights the role of sotatercept in pediatric PAH management, warranting further investigation through prospective studies.
Turns out biology tracks more than we thought — from a spit test that reads your all-nighter to a surgical outcome that still shows up in household chores two decades later. Plus: habits aren't built gradually. They snap.
